Formulation Development
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement With University of Cincinnati to Study for Endometriosis Treatment
Lisata Therapeutics, Inc. recently announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata’s novel cyclic peptide product…
First-Ever Long-Acting Injectable for Malaria Prevention Administered to Study Volunteers
Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial,…
Catalent Boston Adds to Oral Spray Drying Capacity & Capabilities to Support Late-Stage Clinical Trials & Commercialization
Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies, and flexible manufacturing, has completed a series of upgrades to its large-scale spray…
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell & NK Cell Engagers Antibody Platform
Purple Biotech Ltd. recently announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organization for Research and Treatment…
Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma, Inc. recently announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates…
Interius BioTherapeutics Doses First Patient With In Vivo Chimeric Antigen Receptor Gene Therapy for B-Cell Malignancies
Interius BioTherapeutics recently announced the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy…
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor
Nimbus Therapeutics, LLC recently announced it presented preclinical data on its new development candidate, NTX-452, a novel Werner syndrome helicase (WRN) inhibitor, at the 36th…
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza recently announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. The extended agreement will expand…
PolTREG Launches Phase 2 Cell Therapy Trial in Children With Presymptomatic Diabetes
PolTREG S.A. has launched a placebo-controlled Phase 2 clinical trial with PTG-007 Treg cell therapy in presymptomatic type-1 diabetes (T1D) patients, after receiving approval from…
Rentschler Biopharma Announces Largest Single Investment at its Headquarters in Germany
Rentschler Biopharma SE recently announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to…
Rhythm Pharmaceuticals & Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. and Axovia Therapeutics Ltd. recently announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). “We believe there…
UPM Biomedicals Launches FibGel, World’s First Injectable Nanocellulose Hydrogel for Medical Devices
UPM Biomedicals recently announced the launch of FibGel, a natural injectable hydrogel for permanent implantable medical devices. FibGel is a nanofibrillar cellulose hydrogel made from…
GRI Bio Raises $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio, Inc. recently announced it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares…
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program to Minimize Scarring From Burns
BirchBioMed recently announced the authorization from Health Canada to conduct its Phase 2/3 randomized clinical trial of a naturally based compound, FS2, at multiple centers…
Novadip Reports Promising Interim Results From First-in-Human Proof-of-Concept Trial of New Game Changer in Bone Field
Novadip Biosciences recently announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures…
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION Platform
Avacta Group plc recently announced the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION-enabled drug conjugates. Avacta is…
Immutep Announces First-in-Human Phase 1 Study of IMP761 Progresses to Dose Escalation Portion of Trial
Immutep Limited recently announced the first part (Part A, single dose) of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited…
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Immune Regulator for Treatment of Acute Respiratory Distress Syndrome
BioAegis Therapeutics recently announced the first patient has been enrolled in the company’s Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress…
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications
Biognosys recently announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany. The company…
mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800% increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success…
